A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Oral Multiple Doses of ASP7962 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2015
Price : $35 *
At a glance
- Drugs ASP 7962 (Primary)
- Indications Back pain; Osteoarthritis
- Focus Adverse reactions
- Acronyms MAD
- Sponsors Astellas Pharma Europe Ltd
- 14 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Nov 2015 Planned End Date changed from 1 Jan 2016 to 1 Nov 2015 as per ClinicalTrials.gov record.
- 06 Nov 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2015 as per ClinicalTrials.gov record.